Loading...
Loading...
CMRAW| Name | Value |
|---|---|
| Revenues | 0.4M |
| Cost of Revenue | 0.1M |
| Gross Profit | 0.3M |
| Operating Expense | 2.8M |
| Operating I/L | -2.5M |
| Other Income/Expense | 0.0M |
| Interest Income | 0.0M |
| Pretax | -2.5M |
| Income Tax Expense | 75.3M |
| Net Income/Loss | -77.8M |
Comera Life Sciences Holdings, Inc. is a preclinical stage life sciences company specializing in developing proprietary therapeutics using its SQore platform, which facilitates the conversion of IV biologics to subcutaneous versions. The company's primary product programs include CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications.
